Silverback Therapeutics, Inc. (SBTX)

Class Action & Lead Plaintiff Deadline: January 4, 2022

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Silverback Therapeutics, Inc. ("Silverback” or the "Company") (NASDAQ: SBTX). and certain of its officers, on behalf of shareholders who purchased or otherwise acquired either: (1) Silverback common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering conducted on or about December 3, 2020 (the "IPO" or "Offering"); and/or (2) Silverback securities between December 3, 2020 and September 10, 2021, both dates inclusive (the "Class Period").

 

On or around December 3, 2020, Silverback conducted its initial public offering (“IPO”), offering 11.5 million shares of common stock priced at $21.00.  Then, on September 13, 2021, Silverback issued a press release “announc[ing] that interim data from the dose-escalation portion of its Phase 1/1b clinical trial evaluating SBT6050 as a monotherapy and in combination with pembrolizumab in patients with advanced or metastatic HER2-expressing or amplified solid tumors will be presented at the upcoming European Society for Medical Oncology (ESMO) 2021 Congress from September 16-21, 2021” and advising that “[t]he accepted abstract . . . is now available on the ESMO website.”  Per the abstract, while there was a manageable safety profile for the Company’s experimental therapy, the best overall response was PR (n=1), SD (n=3), and PD (n=10).  On this news, Silberback’s stock price fell $4.54 per share, or 23.35%, to close at $14.90 per share on September 13, 2021.

 

A class action lawsuit has already been filed. You can review a copy of the Complaint and sign the certification form or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Boston Beer you have until November 15, 2021, to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.